COVID Vaccine Developer/Manufacturer Announcements [organizations from WHO EUL/PQ listing above]

Milestones :: Perspectives :: Research


COVID Vaccine Developer/Manufacturer Announcements [organizations from WHO EUL/PQ listing above]


Press Releases – No new digest announcements identified

Bharat Biotech, India
Press Releases – No new digest announcements identified
Apr 21: Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease

Apr 20: Bharat Biotech Announces COVAXIN® Capacity Expansion to Support vaccination campaigns in India and Worldwide.
·Capacity expansion has been implemented across multiple facilities in Hyderabad and Bangalore, to reach ~700 million doses/year, one of the largest production capacities for Inactivated viral vaccines worldwide,
· IMDG agonist molecule synthesis and manufacturing has been successfully implemented in India eliminating dependency on imports,
· Raw materials, packing materials and single use consumables for manufacturing have been secured to meet our capacity requirements

BioCubaFarma – Cuba
Últimas Noticias
Comenzó segunda fase de ensayos clínicos del candidato vacunal Soberana Plus
Con la vacunación de una veintena de personas comenzó este sábado en el capitalino Instituto de Hematología e Inmunología, la fase II A de los ensayos clínicos con el candidato vacunal cubano anti-COVID-19 Soberana Plus, desarrollado por el Instituto Finlay de Vacunas (IFV)…


News – No new digest announcements identified

Clover Biopharmaceuticals – China
News – Website under maintenance


Curevac [Bayer Ag – Germany]
April 19, 2021
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic


Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

Home – No new digest announcements identified


Press Releases
Apr 23, 2021 United States
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
… Johnson & Johnson has updated the EUA Fact Sheets for Healthcare Providers Administering Vaccine (Vaccination Providers), and Recipients and Caregivers for the Company’s COVID-19 vaccine, to include information about the diagnosis and treatment of thrombosis with thrombocytopenia. The revised EUA fact sheets is available at:

Apr 23, 2021 United States
Johnson & Johnson Statement on April 23 CDC Advisory Committee Meeting on Company COVID-19 Vaccine
… Statement from Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson: “We are grateful to the Advisory Committee and its medical experts for the rigorous evaluation of our COVID-19 vaccine. The Committee’s recommendation is an essential step toward continuing urgently needed vaccinations in a safe way for millions of people in the U.S. As the global pandemic continues to devastate communities around the world, we believe a single-shot, easily transportable COVID-19 vaccine with demonstrated protection against multiple variants can help protect the health and safety of people everywhere. We will continue to collaborate with the CDC, FDA and health authorities around the world, including the European Medicines Agency and the World Health Organization, to ensure this very rare event can be identified early and treated effectively. We remain committed to the health and safety of people worldwide.”


Press Releases
April 20, 2021
Moderna Announces New Supply Agreement with Israel for 2022
:: First firm order reached with the Company for 2022 supply
:: Israel also retains an option to purchase doses of variant-specific vaccine booster candidate, pending regulatory approval


Press Releases – No new digest announcements identified


Recent Press Releases
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®


Serum Institute of India
Wednesday, April 21, 2021
Media Statement
Serum Institute of India (SII), welcomes the recent announcement made by Government of India’s Ministry of Health and Finance Ministry to accelerate India’s vaccination drive. The promising directives will help to scaleup vaccine production, and allow state governments, private hospitals, and vaccination centers to procure vaccines directly.
For the next two months, we will address the limited capacity by scaling up the vaccine production. Going ahead, 50% of our capacities will be served to the Government of India’s vaccination program, and the remaining 50% of the capacity will be for the State governments and private hospitals.
…Considering the global vaccine prices, we are ensuring that our vaccines are affordable in comparison to any other vaccines in the world.
… Furthermore, owing to the complexity, and urgency of the situation it is challenging to supply it independently to each corporate entity. We would urge all corporate and private individuals to access the vaccines through the state facilitated machinery and private health systems. Post 4-5 months, the vaccines will be made available in retail and free trade.
We at Serum, would like to assure you that we will continue to do our best to help everyone and would request you all to be patient with us.


News – No new digest announcements identified


Press Releases – No new digest announcements identified


Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]